[1]
|
Logo placeholder
|
| Location |
Vancouver, Canada |
| Type |
University |
| Website |
https://www.ubc.ca/ |
| Focus Areas |
Alzheimer's Disease, APP, Oxidative stress |
| Departments |
Alzheimer's Disease Research Center |
University Of British Columbia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
University of British Columbia is a university located in Vancouver, Canada. The institution is recognized for its contributions to neurodegenerative disease research, with focus areas including [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [APP[/entities/[app-protein[/entities/[app-protein[/entities/[app-protein--TEMP--/entities)--FIX--, Oxidative stress.
University of British Columbia hosts 1 researchers tracked in the NeuroWiki database and maintains 1 department dedicated to neuroscience research. The institution's research programs span Alzheimer's Disease, APP, Oxidative stress, contributing to both basic science understanding and translational approaches for neurodegenerative conditions. [2]
Through its Alzheimer's Disease Research Center, University of British Columbia supports multidisciplinary investigation into the mechanisms, diagnosis, and treatment of neurodegenerative diseases. The institution's researchers have published extensively on topics including Alzheimer's Disease, APP, Oxidative stress and continue to advance the field through clinical trials, biomarker development, and fundamental neuroscience research.
- [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- APP
- Oxidative stress
¶ Departments and Centers
- Alzheimer's Disease Research Center
- Basic and translational neuroscience teams at University of British Columbia study disease mechanisms across molecular, cellular, and systems levels.
- Programs align discovery cohorts, imaging, biomarkers, and interventional studies to improve diagnosis and trial readiness.
- Cross-disciplinary collaboration between neurology, psychiatry, and data science teams enables integrated neurodegenerative disease research.
¶ Neurodegenerative Programs and Key Labs
Program-level enrichment pending curation for this institution.
¶ Key Labs and Research Groups
Lab-level enrichment pending curation for this institution.
- Advanced research programs in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
- Built translational pipelines spanning discovery science, biomarker validation, and clinical studies at University of British Columbia.
- Contributed investigator networks and multi-site collaborations that support reproducible neurodegeneration research.
| Researcher |
H-index |
Focus Areas |
| [Weihong Song[/researchers/[weihong-song[/researchers/[weihong-song[/researchers/[weihong-song--TEMP--/researchers)--FIX-- |
120 |
Alzheimer's Disease |
¶ Clinical and Translational Impact
The neurodegenerative disease portfolio at University of British Columbia supports a continuum from mechanism-focused laboratory research to patient-oriented studies. Institutional investigators contribute to biomarker qualification, patient stratification frameworks, and trial endpoint development that can accelerate therapeutic evaluation.
By combining longitudinal cohorts with mechanistic expertise, the institution helps connect observations from [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/diseases pages to hypotheses represented across [Mechanisms Index[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms. This translational model helps prioritize therapies with stronger biological rationale and clearer paths to testing.
The institution's programs also contribute to workforce development through training programs, collaborative grants, and open-science dissemination. These activities strengthen cross-site reproducibility and enable tighter integration between basic neuroscience discoveries and clinical decision-making.
- [Researchers and Institutions Index[/[researchers[/[researchers[/[researchers[/[researchers[/researchers
- [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [Mechanisms Index[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
- [Clinical Trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials
The study of University Of British Columbia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- University of British Columbia official website
- NeuroWiki researcher database. Internal resource.
- Selected publications listed in the Key Publications section (DOI links where available).
- Page auto-generated from NeuroWiki institution database. Last updated: 2026-02-26.
- Institutional research reports and publications.
- Page updated: 2026-03-01
- This institution contributes to neurodegeneration research through a portfolio model that combines basic neuroscience, translational biomarker programs, and clinical research infrastructure. In practice, the highest-impact outputs usually come from coordinated programs across departments rather than isolated projects. Readers should therefore interpret this page together with [Institutions Index[/[institutions[/[institutions[/[institutions[/[institutions[/institutions, [Researchers Index[/[researchers[/[researchers[/[researchers[/[researchers[/researchers, and disease pages including [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, and [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--.
- A useful portfolio lens includes three operational layers. The first layer is mechanism discovery, where labs investigate molecular pathways such as [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--, tau]/clinical trials/clinical-trials).
- For NeuroWiki maintenance, institution pages should be treated as navigation hubs. As new programs, datasets, and trial outputs are published, cross-links should be propagated to related mechanism, gene, protein, and treatment pages so users can move from organizational context to evidence context without losing traceability.